Mohamed G Atta1, Michelle M Estrella2, Karl L Skorecki3, Jeffrey B Kopp4, Cheryl A Winkler5, Walter G Wasser6, Revital Shemer3, Lorraine C Racusen7, Michael Kuperman8, Matthew C Foy9, Gregory M Lucas2, Derek M Fine2. 1. Departments of Medicine and matta1@jhmi.edu. 2. Departments of Medicine and. 3. Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel; Department of Medicine, Rambam Health Care Campus, Haifa, Israel; 4. Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; 5. Basic Research Laboratory, Center for Cancer Research, National Cancer Institute Frederick, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland; 6. Department of Medicine, Rambam Health Care Campus, Haifa, Israel; 7. Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland; 8. Department of Pathology, Baylor University Medical Center, Dallas, Texas; and. 9. Division of Internal Medicine, Louisiana State University Health Science Center, Baton Rouge, Louisiana.
Abstract
BACKGROUND AND OBJECTIVES: Prior studies have shown that the APOL1 risk alleles are associated with a greater risk of HIV-associated nephropathy and FSGS among blacks who are HIV positive. We sought to determine whether the APOL1 high-risk genotype incrementally improved the prediction of these underlying lesions beyond conventional clinical factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a cross-sectional study, we analyzed data from 203 blacks who are HIV positive, underwent kidney biopsies between 1996 and 2011, and were genotyped for the APOL1 G1 and G2 alleles. Predictive logistic regression models with conventional clinical factors were compared with those that also included APOL1 genotype using receiver-operating curves and bootstrapping analyses with crossvalidation. RESULTS: The addition of APOL1 genotype to HIV-related risk factors for kidney disease in a predictive model improved the prediction of non-HIV-associated nephropathy FSGS, specifically, increasing the c statistic from 0.65 to 0.74 (P=0.04). Although two risk alleles were significantly associated with higher odds of HIV-associated nephropathy, APOL1 genotype did not add incrementally to the prediction of this specific histopathology. CONCLUSIONS: APOL1 genotype may provide additional diagnostic information to traditional clinical variables in predicting underlying FSGS spectrum lesions in blacks who are HIV positive. In contrast, although APOL1 risk genotype predicts HIV-associated nephropathy, it lacked a high c statistic sufficient for discrimination to eliminate the role of kidney biopsy in the clinical care of blacks who are HIV positive with nephrotic proteinuria or unexplained kidney disease.
BACKGROUND AND OBJECTIVES: Prior studies have shown that the APOL1 risk alleles are associated with a greater risk of HIV-associated nephropathy and FSGS among blacks who are HIV positive. We sought to determine whether the APOL1 high-risk genotype incrementally improved the prediction of these underlying lesions beyond conventional clinical factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a cross-sectional study, we analyzed data from 203 blacks who are HIV positive, underwent kidney biopsies between 1996 and 2011, and were genotyped for the APOL1 G1 and G2 alleles. Predictive logistic regression models with conventional clinical factors were compared with those that also included APOL1 genotype using receiver-operating curves and bootstrapping analyses with crossvalidation. RESULTS: The addition of APOL1 genotype to HIV-related risk factors for kidney disease in a predictive model improved the prediction of non-HIV-associated nephropathy FSGS, specifically, increasing the c statistic from 0.65 to 0.74 (P=0.04). Although two risk alleles were significantly associated with higher odds of HIV-associated nephropathy, APOL1 genotype did not add incrementally to the prediction of this specific histopathology. CONCLUSIONS:APOL1 genotype may provide additional diagnostic information to traditional clinical variables in predicting underlying FSGS spectrum lesions in blacks who are HIV positive. In contrast, although APOL1 risk genotype predicts HIV-associated nephropathy, it lacked a high c statistic sufficient for discrimination to eliminate the role of kidney biopsy in the clinical care of blacks who are HIV positive with nephrotic proteinuria or unexplained kidney disease.
Authors: David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: Derek M Fine; Walter G Wasser; Michelle M Estrella; Mohamed G Atta; Michael Kuperman; Revital Shemer; Arun Rajasekaran; Shay Tzur; Lorraine C Racusen; Karl Skorecki Journal: J Am Soc Nephrol Date: 2011-12-01 Impact factor: 10.121
Authors: Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: Natalia Papeta; Krzysztof Kiryluk; Ami Patel; Roel Sterken; Nilgun Kacak; Holly J Snyder; Phil H Imus; Anand N Mhatre; Anil K Lawani; Bruce A Julian; Robert J Wyatt; Jan Novak; Christina M Wyatt; Michael J Ross; Jonathan A Winston; Mary E Klotman; David J Cohen; Gerald B Appel; Vivette D D'Agati; Paul E Klotman; Ali G Gharavi Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Santhi Ganesan; Leslie A Bruggeman; John R Sedor Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: Gregory M Lucas; Bryan Lau; Mohamed G Atta; Derek M Fine; Jeanne Keruly; Richard D Moore Journal: J Infect Dis Date: 2008-06-01 Impact factor: 5.226
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Elaine Ku; Michael S Lipkowitz; Lawrence J Appel; Afshin Parsa; Jennifer Gassman; David V Glidden; Miroslaw Smogorzewski; Chi-Yuan Hsu Journal: Kidney Int Date: 2016-12-04 Impact factor: 10.612
Authors: Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt Journal: Kidney Int Date: 2018-02-03 Impact factor: 10.612
Authors: Nazik Elmalaika Husain; Mohamed H Ahmed; Ahmed O Almobarak; Sufian K Noor; Wadie M Elmadhoun; Heitham Awadalla; Clare L Woodward; Dushyant Mital Journal: J Clin Med Res Date: 2017-12-01
Authors: Teresa K Chen; Ronit Katz; Michelle M Estrella; Orlando M Gutierrez; Holly Kramer; Wendy S Post; Michael G Shlipak; Christina L Wassel; Carmen A Peralta Journal: J Am Heart Assoc Date: 2017-12-21 Impact factor: 5.501